

# Molecular Pathways: Isocitrate Dehydrogenase Mutations in Cancer

Owen Clark<sup>1</sup>, Katharine Yen<sup>2</sup>, and Ingo K. Mellinghoff<sup>1,3,4</sup>

## Abstract

IDH1 and IDH2 are homodimeric enzymes that catalyze the conversion of isocitrate to  $\alpha$ -ketoglutarate ( $\alpha$ -KG) and concomitantly produce reduced NADPH from NADP<sup>+</sup>. Mutations in the genes encoding IDH1 and IDH2 have recently been found in a variety of human cancers, most commonly glioma, acute myeloid leukemia (AML), chondrosarcoma, and intrahepatic cholangiocarcinoma. The mutant protein loses its normal enzymatic activity and gains a new ability to produce the "oncometabolite" R(-)-2-hydroxyglutarate (R-2-HG). R-2-HG competitively inhibits

$\alpha$ -KG-dependent enzymes which play crucial roles in gene regulation and tissue homeostasis. Expression of mutant IDH impairs cellular differentiation in various cell lineages and promotes tumor development in cooperation with other cancer genes. First-generation inhibitors of mutant IDH have entered clinical trials, and have shown encouraging results in patients with IDH-mutant AML. This article summarizes recent progress in our understanding of the role of mutant IDH in tumorigenesis. *Clin Cancer Res*; 22(8); 1837–42. ©2016 AACR.

## Background

The first identification of a cancer-associated isocitrate dehydrogenase (*IDH*) mutation was in a patient with colorectal cancer, and emerged from one of the earliest comprehensive analyses of mutations in protein-coding genes (1). Two years later, the same group reported a substantially higher frequency of *IDH* mutations (12%) when they applied whole genome sequencing to a small number of glioblastomas, the most common malignant brain tumor in adults (2). Interestingly, the majority of *IDH*-mutant glioblastomas (5/6) were from patients whose tumors had developed overtime from lower grade (WHO grade II and WHO grade III) tumors. This seminal finding was confirmed in a follow-up study with a much larger number of tumors, which reported *IDH* mutations found in the vast majority (>70%) of WHO grade II and WHO grade III gliomas (3).

Since these initial studies, many human cancers were examined for the presence of mutations in *IDH1* and *IDH2*. *IDH* mutations were observed in a number of hematopoietic neoplasms, most commonly acute myeloid leukemia (AML; ~10%–15%; refs. 4–6) and angio-immunoblastic T-cell lymphoma (~20%; ref. 7). *IDH* mutations were also found in chondrosarcoma (~50%; ref. 8), intrahepatic cholangiocarcinoma (~15%–20%; ref. 9), and at lower frequency (<5%) in other solid tumors (e.g., glioblastomas, colorectal cancer, esophageal cancer, bladder cancer, melanoma, prostate carcinoma, breast adenocarcinoma; ref. 10). Somatic heterozygous mutations in *IDH1* or *IDH2* were also found in the majority of enchondromas and spindle cell hemangiomas in

patients with the Ollier disease and Maffucci syndrome, nonhereditary skeletal disorders (11).

More recent DNA resequencing projects have provided additional information regarding the timing of *IDH* mutations during tumor development. Analyzing over 300 gliomas, Watanabe and colleagues found that in 51 cases with multiple biopsies, neither acquisition of a mutation in *TP53* nor loss of 1p/19q occurred prior to a mutation in *IDH1* (12). Further analysis of matched biopsy pairs, collected from glioma patients at the initial diagnosis and at the time of tumor recurrence showed that *IDH1*<sup>R132H</sup> was the only mutation that was consistently present in both the initial and recurrent biopsy specimen (13). In leukemia patients, *IDH2* mutations were observed in the absence of *NPM1c* mutations in both mature and progenitor cell populations, suggesting that *IDH2* mutation might be an early and perhaps preleukemic event (14, 15).

The vast majority of cancer-associated mutations in *IDH1* and *IDH2* map to an arginine within the catalytic pocket of the enzyme. Mutations in *IDH1* mostly occur at arginine 132, with substitutions including R132H, R132C, R132L, R132S, and R132G. Mutations in *IDH2* typically occur at arginine 172 or arginine 140 (which is analogous to R132 in *IDH1*). The clustering of cancer-associated *IDH* mutations in the functional domain of the enzyme suggested that these mutations might endow the mutant protein with a novel and presumably oncogenic enzymatic activity. This question has been explored through untargeted metabolomic profiling of cells engineered to express the mutant enzyme. Compared with parental cells, cells expressing the *IDH1*<sup>R132H</sup>-mutant enzyme were found to produce the R(-) enantiomer of the metabolite 2-hydroxyglutarate (R-2-HG), which accumulates in *IDH*-mutant human gliomas (16) and leukemias (5, 17). Production of R-2-HG involves direct conversion from  $\alpha$ -KG and relies on the presence of a wild-type allele (18), likely explaining the rareness of loss of heterozygosity.

The identification of an "oncometabolite" in *IDH*-mutant tumors strengthened the hypothesis that *IDH* mutations are oncogenic, and led many investigators to examine the ability of mutant *IDH* to transform nonmalignant cells. Expression of mutant *Idh* in mouse myeloid progenitor 32D cells and primary

<sup>1</sup>Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, New York. <sup>2</sup>Agios Pharmaceuticals, Cambridge, Massachusetts. <sup>3</sup>Department of Neurology, Memorial Sloan-Kettering Cancer Center, New York, New York. <sup>4</sup>Department of Pharmacology, Weill-Cornell Graduate School of Biomedical Sciences, New York, New York.

**Corresponding Author:** Ingo K. Mellinghoff, 1275 York Avenue, Box 20, New York, NY 10021. Phone: 646-888-2766; Fax: 646-422-0856; E-mail: mellingi@mskcc.org

**doi:** 10.1158/1078-0432.CCR-13-1333

©2016 American Association for Cancer Research.

mouse bone marrow cells impaired hematopoietic differentiation and increased stem/progenitor cell marker expression, suggesting a proleukemogenic effect (19). A more recent study reported that retrovirally mediated expression of mutant *Idh2*<sup>R140Q</sup> in murine primary hematopoietic bone marrow stem and progenitor cell populations induced myeloproliferative-like neoplasms, T-cell lymphoma or B-cell lymphoma when transplanted into irradiated mice (20). However, these hematologic malignancies occurred at low penetrance and with long latency, suggesting that they did not arise solely due to mutant *Idh2* expression. Expression of mutant *Idh2* in a nontransformed mesenchymal multipotent mouse cell line (C3H, 10T) impaired their differentiation into adipocytic and chondrocytic lineages and resulted in loss of contact inhibition and tumor formation *in vivo* (21). In immortalized human astrocytes, expression of mutant *IDH*, but not wild-type *IDH* or a catalytically inactive *IDH* mutant promoted their anchorage-independent growth (22).

Further insights into the role of mutant *IDH* in tumor initiation have emerged from experiments with genetically engineered mice. Tamoxifen-induced global expression of *Idh2*<sup>R140Q</sup> or *R172K*, driven from the chicken  $\beta$ -actin promoter, resulted in cardiomyopathy, white matter abnormalities throughout the central nervous system, and muscular dystrophy; mice engineered to express mutant *Idh2* in specific tissues reportedly developed carcinomas with very long latencies (23). In another model, mice that expressed a doxycycline-inducible *Idh2*<sup>R140Q</sup> allele from the Collagen A1 locus did not develop leukemia, even after one year of continuous doxycycline treatment (24). The most common cancer-associated *IDH* mutation, *IDH1*<sup>R132H</sup>, has also been inserted into the endogenous murine *Idh1* locus and expression of the mutant enzyme subsequently targeted to specific cell populations. Expression of *Idh1*<sup>R132H</sup> in hematopoietic cells (using the LysM and Vav promoters to express Cre-recombinase) resulted in increased numbers of hematopoietic progenitors, but no overt leukemia (25). Expression of *Idh1*<sup>R132H</sup> in nestin (*Nes*)-expressing neural stem cells resulted in perinatal lethality due to cerebral hemorrhage (26). Expression of *Idh1*<sup>R132H</sup> in GFAP-expressing astrocytes resulted in impaired collagen maturation and basement membrane function, but again no tumors. Tamoxifen-inducible expression of mutant *Idh1* in chondrocytes (using the *Col2A1* promoter to express Cre recombinase) resulted in enchondromas, benign cartilage tumors that are precursors to malignant chondrosarcomas (27). Doxycycline-induced expression of mutant *Idh2* (*Idh2*<sup>R140Q</sup> or *Idh2*<sup>R172K</sup>) increased hepatocyte proliferation in a liver injury model, but was not sufficient to induce tumors (28).

More recent studies have examined whether *IDH* mutations might collaborate with other genetic events to induce cancer in mice. Using a mouse transplantation assay, Chaturvedi and colleagues found that mutant *IDH1* was not sufficient to transform hematopoietic cells but accelerated the onset of leukemia in cooperation with *HoxA9* (29). Chen and colleagues applied a mosaic mouse modeling approach in which hematopoietic stem and progenitor cells (HPSC) from *Flt3-ITD* or *Nras*<sup>G12D</sup> mice were transduced with a retroviral vector expressing mutant *Idh2* and then assessed for tumorigenic potential following transplantation into syngeneic recipient mice. *Idh2* mutants were found to cooperate with *Flt3* or *Nras* alleles to drive leukemia formation (30). Cooperativity between mutant *Idh2*<sup>R140Q</sup> and other leukemia-relevant pathway alterations (e.g., *Flt3-ITD* or homeobox proteins *HoxA9* and *Meis1a*) was confirmed in the aforementioned doxy-

cycline-inducible mouse model (24) and, more recently, another mosaic mouse modeling approach (31). Saha and colleagues showed that *Idh2*<sup>R172K</sup> cooperated with mutant KRAS (*Kras*<sup>G12D</sup>) to induce intrahepatic cholangiocarcinomas (28). In aggregate, these studies demonstrate that mutant *IDH* cooperates with other oncogenic events to initiate cancer, consistent with the finding that *IDH*-mutant human cancers typically harbor alterations in multiple other cancer genes. In glioma, for example, *IDH* mutations are associated with missense mutations in *ATRX*, *TP53*, and *TERT* (diffuse astrocytomas) or codeletion of chromosome arms 1p and 19q (oligodendrogliomas; refs. 32,33). In AML patients with a normal cytogenetic profile, *IDH* mutations are associated with mutations in *NPM1*, *FLT3-ITD*, and *DNMT3A* (refs. 34, 35; Fig. 1).


Recent studies have begun to address the question of whether the activity of the mutant *IDH* enzyme remains important for the growth of *IDH*-mutant cancers once they are fully established. Studies in experimental cancer models suggest that this is indeed the case, with the strongest evidence coming from leukemia models. In TF-1 human erythroleukemia cells, ectopic expression of mutant *IDH* promotes growth factor independence, a phenotype that can be reversed with a small-molecule mutant *IDH* inhibitor (36, 37). *Ex vivo* treatment of freshly isolated *IDH*-mutant leukemic blasts with a mutant selective *IDH* inhibitor induces a cellular differentiation program (36). Pharmacologic inhibition of the mutant *IDH* enzyme blocks colony formation of human AML cells but not of normal CD34<sup>+</sup> bone marrow cells (29). In a genetically engineered leukemia model, pharmacologic or genetic inhibition of mutant *Idh2* triggered the differentiation and death of AML cells (30), and doxycycline-induced silencing of mutant *Idh2* similarly eliminated *Idh2*<sup>R140Q</sup>/*Hoxa9* or *Idh2*<sup>R140Q</sup>/*Meis1a*-driven leukemia cells (24).

## Clinical-Translational Advances

The above mentioned results in experimental leukemia models are supported by the preliminary findings of an ongoing phase 1 clinical trial, which showed that the mutant *IDH2* inhibitor AG-221 produces clinical responses, including complete and durable responses, in about 40% of patients with AML and MDS (38).

The contribution of the mutant enzyme to the maintenance of *IDH*-mutant solid tumors remains currently unknown, and further insights are likely to emerge from an ongoing single-arm dose escalation study (ClinicalTrials.gov NCT02073994) with the mutant-selective *IDH1* inhibitor AG-120 (39). Data from experimental models suggest that *IDH1*-mutant solid tumors remain, at least in part, dependent on the activity of the mutant enzyme. In HT1080 human fibrosarcoma cells, RNAi-mediated suppression of endogenous mutant *IDH1* significantly inhibited anchorage-independent growth (40). Knocking out the endogenous mutant *IDH1* gene using TALEN technology similarly impaired anchorage-independent growth and *in vivo* growth of *IDH*-mutant human sarcoma cells (41). In *IDH1*-mutant glioma cells, pharmacologic blockade of the mutant enzyme retarded their growth in soft agar and in mice (42).

Targeted therapy of *IDH*-mutant cancers is likely to grow beyond inhibition of the mutant enzyme itself and may include strategies directed against the epigenetic and metabolic changes that are associated with *IDH* mutations. Current data suggest that the R-2-HG "oncometabolite" is responsible for many, if not all, biologic effects of cancer-associated *IDH* mutations. Cell-permeable



**Figure 1.**

Co-occurring genetic lesions in *IDH*-mutant glioma and AML. OncoPrint figure (generated using Memorial Sloan Kettering cBio Portal; ref. 10) showing frequency of commonly co-occurring genetic lesions in glioma (top) and AML (bottom). Note that *TET2* is shown to illustrate near complete mutual exclusivity with mutations in *IDH1/2*. Results are based upon data generated by the TCGA Research Network: Glioma data set (ref. 32); AML dataset (73). For simplicity changes in copy number were not included. *TET2*, Tet Methylcytosine Dioxygenase 2; *DNMT3A*, DNA (Cytosine-5-)-Methyltransferase 3 Alpha; *FLT3*, Fms-Related Tyrosine Kinase 3; *NPM1*, Nucleophosmin (Nucleolar Phosphoprotein B23, Numatrin); *TP53*, Tumor Protein P53; *ATRX*, Alpha Thalassemia/Mental Retardation Syndrome X-Linked.


esters of R-2-HG phenocopy the effects of mutant *IDH* in experimental models (43), and ectopic expression of the dehydrogenase (44) that converts R-2-HG into  $\alpha$ -KG, and thus counteracts the activity of the mutant IDH enzyme, is sufficient to reverse the cellular effects of cancer-associated *IDH* mutants (45). R-2-HG competitively inhibits a large family of  $\alpha$ -KG-dependent enzymes, a protein family with over 60 members. These include the ten-eleven translocation (TET) family of 5-methyl cytosine hydroxylases, the jumoni domain containing (JmjC) family of histone lysine demethylases (46, 47), enzymes involved in nucleic acid metabolism (AlkB, FTO), and many enzymes with still unknown functions (ref. 48; Fig. 2).

It is currently unknown which  $\alpha$ -KG-dependent enzymes function as context-dependent tumor suppressors and are inhibited at the relevant R-2-HG concentrations in human tumors. Inhibition of *TET2* is likely to mediate the effects of mutant *IDH* in AML, given the well documented role of *TET2* in hematopoietic differentiation, the almost completely mutual exclusivity of *TET2* and *IDH* mutations in AML (Fig. 1), the decreased 5-hydroxymethylcytosine (5-hmC) levels in *IDH*-mutant AMLs, and the identification of *TET2* as a candidate effector of mutant *IDH* in a short hairpin RNA library screen of  $\alpha$ -KG-dependent dioxygenases (19, 37, 49–51). Inhibition of the histone demethylases JMJD2A and JMJD2C likely contributes to the effects of mutant *IDH* on cellular differentiation in many cell lineages. These enzymes are particularly sensitive to inhibition by R-2-HG (46, 47), and knockdown of *Jmjd2C* (also known as *Kdm4c*) was sufficient to phenocopy the effects of mutant *Idh* on adipocyte differentiation in 3T3-L1 cells (43). In fact, it seems plausible that many hallmarks of mutant *IDH*-associated human malignancies, such as restricted cellular differentiation and DNA hypermethylation, result from coordi-

nate effects of R-2-HG on DNA and histone methylation (43,52). These findings raise the intriguing question of whether *IDH*-mutant cancer cells might show an increased sensitivity to the DNA methyltransferase inhibitors decitabine or 5-azacytidine (53–55) or drugs targeting histone modifications.

It is less clear whether epigenetic alterations are also responsible for the oncogenic effects of mutant *IDH* in solid tumors. We observed that growth inhibition of *IDH1*-mutant glioma xenografts by a mutant-selective *IDH1* inhibitor was not clearly linked to epigenetic changes in tumor tissue (42). Similarly, ectopic expression of the R-2-HG-dehydrogenase in HT1080 sarcoma cells effectively inhibited their growth *in vivo* without clear changes in histone methylation marks or *TET2*-induced 5-hmC production (41). It is plausible that the oncogenic effects of mutant *IDH* in solid tumors are linked to metabolic alterations associated with *IDH* mutations, including reductions in  $\alpha$ -KG levels, changes in the NADP<sup>+</sup>/NADPH ratio and mitochondrial bioenergetics, and an impaired ability of the IDH enzyme to catalyze the reverse carboxylation of  $\alpha$ -KG to form isocitrate. These metabolic changes can have a profound effect on the ability of cells to proliferate, differentiate, and escape cell death, and may introduce therapeutic vulnerabilities (56–64). Recent studies reported an enhanced susceptibility of *IDH1*-mutant cancers to inhibitors of BCL-2 (63), due to the effect of mutant IDH on mitochondrial bioenergetics, or to depletion of the coenzyme NAD<sup>+</sup> (65).

The success of therapeutic strategies to curb the growth of *IDH*-mutant cancers will hinge on a deeper understanding of the molecular mechanisms of *IDH*-associated tumorigenesis, and R-2-HG effector pathways, in each cancer type. In addition to the epigenetic and metabolic effects of mutant *IDH* outlined above, R-2-HG has been reported to stimulate the activity



**Figure 2.**

Molecular mechanisms of *IDH*-associated tumorigenesis. Wild-type *IDH1/2* (wtIDH1/2) converts isocitrate (generated through the citric acid (TCA) cycle) into  $\alpha$ -KG, producing NADPH in the process. Mutant *IDH1/2* (mutIDH1/2) converts  $\alpha$ -KG to the oncometabolite R-2-HG, consuming NADPH. R-2-HG inhibits members of the protein family of  $\alpha$ -KG-dependent dioxygenases. Epigenetic modifications result from inhibition of histone lysine demethylases (KDM) and the 5-methyl cytosine hydroxylase TET2. Inhibition of prolyl-hydroxylase impairs collagen maturation. R-2-HG has been reported to activate the enzyme prolyl-hydroxylase 2 (PHD2) that inhibits hypoxia-inducible factor 1- $\alpha$  (HIF-1 $\alpha$ ; ref. 22), although other studies suggest that it may be inhibited (46, 47). Mutant *IDH* may also change the cellular redox environment by altering the ratio of NADPH to NADP<sup>+</sup>. *IDH3* has been omitted from this figure for simplicity.

Downloaded from <http://aacrjournals.org/clinccancerres/article-pdf/22/8/1837/2038079/1837.pdf> by guest on 13 January 2025

of the EGLN prolyl 4-hydroxylases, leading to diminished levels of hypoxia-inducible transcription factor (HIF) and enhanced soft agar growth of human astrocytes (66). Consistent with this result, the expression of HIF1 $\alpha$ -responsive genes, including many essential for glycolysis, appears to be lower in *IDH*-mutant gliomas (67), perhaps explaining the often poor retention of the radiotracer 2-[(18)F] Fluoro-2-deoxy-D-glucose (FDG) by these tumors. The group of  $\alpha$ -KG-dependent dioxygenases also includes enzymes that hydroxylate proline and lysine residues in collagen and promote its stability. It is intriguing to speculate that the observed

brain hemorrhages in *Nes-Cre Idh1<sup>R132H</sup>* mice might have resulted from impaired collagen maturation and basement membrane architecture (68).

A remarkable body of knowledge has been generated in the few years since the first description of cancer-associated *IDH* mutations, and the future seems bright for the development of rationale therapeutic approaches to *IDH*-mutant cancers. The ability to monitor the activity of the mutant *IDH* enzyme through quantification of R-2-HG levels in blood (69) or magnetic resonance spectroscopy in tumors (70–72) will be instrumental in developing such strategies.

## Disclosure of Potential Conflicts of Interest

K. Yen has ownership interest (including patents) in Agios Pharmaceuticals. No potential conflicts of interest were disclosed by the other authors.

## Disclaimer

The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

## Authors' Contributions

**Conception and design:** O. Clark, I.K. Mellinghoff  
**Development of methodology:** O. Clark, I.K. Mellinghoff  
**Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.):** O. Clark, I.K. Mellinghoff  
**Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis):** O. Clark, I.K. Mellinghoff  
**Writing, review, and/or revision of the manuscript:** O. Clark, K. Yen, I.K. Mellinghoff

## References

- Sjblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, et al. The consensus coding sequences of human breast and colorectal cancers. *Science* 2006;314:268–74.
- Parsons DW, Jones S, Zhang X, Lin JCH, Leary RJ, Angenendt P, et al. An Integrated genomic analysis of human glioblastoma multiforme. *Science* 2008;321:1807–12.
- Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, et al. IDH1 and IDH2 mutations in gliomas. *N Engl J Med* 2009;360:765–73.
- Mardis ER, Ding L, Dooling DJ, Larson DE, McLellan MD, Chen K, et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. *N Engl J Med* 2009;361:1058–66.
- Gross S, Cairns RA, Minden MD, Driggers EM, Bittinger MA, Jang HG, et al. Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. *J Exp Med* 2010;207:339–44.
- Marcucci G, Maharry K, Wu YZ, Radmacher MD, Mrozek K, Margeson D, et al. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. *J Clin Oncol* 2010;28:2348–55.
- Cairns RA, Iqbal J, Lemonnier F, Kucuk C, de Leval L, Jais J-P, et al. IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma. *Blood* 2012;119:1901–3.
- Amary MF, Bacci K, Maggiani F, Damato S, Halai D, Berisha F, et al. IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours. *J Pathol* 2011;224:334–43.
- Borger DR, Tanabe KK, Fan KC, Lopez HU, Fantin VR, Straley KS, et al. Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. *Oncol* 2012;17:72–9.
- Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. *Cancer Discov* 2012;2:401–4.
- Pansuriya TC, van Eijk R, d'Adamo P, van Ruler MA, Kuijjer ML, Oosting J, et al. Somatic mosaic IDH1 and IDH2 mutations are associated with enchondroma and spindle cell hemangioma in Ollier disease and Maffucci syndrome. *Nat Genet* 2011;43:1256–61.
- Watanabe T, Nobusawa S, Kleihues P, Ohgaki H. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. *Am J Pathol* 2010;174:1149–53.
- Johnson BE, Mazar T, Hong C, Barnes M, Aihara K, McLean CY, et al. Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. *Science* 2014;343:189–93.
- Corces-Zimmerman MR, Hong WJ, Weissman IL, Medeiros BC, Majeti R. Pre-leukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission. *Proc Natl Acad Sci USA* 2014;111:2548–53.
- Shlush LI, Zandi S, Mitchell A, Chen WC, Brandwein JM, Gupta V, et al. Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. *Nature* 2014;1–13.
- Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. *Nature* 2009;462:739–44.
- Ward PS, Patel J, Wise DR, Abdel-Wahab O, Bennett BD, Collier HA, et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. *Cancer Cell* 2010;17:225–34.
- Jin G, Reitman ZJ, Duncan CG, Spasojevic I, Gooden DM, Rasheed BA, et al. Disruption of wild-type IDH1 suppresses D-2-hydroxyglutarate production in IDH1-mutated gliomas. *Cancer Res* 2013;73:496–501.
- Figueroa ME, Abdel-Wahab O, Lu C, Ward PS, Patel J, Shih A, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. *Cancer Cell* 2010;18:553–67.
- Mylonas E, Janin M, Bawa O, Opolon P, David M, Quivoron C, et al. Isocitrate dehydrogenase (IDH)2 R140Q mutation induces myeloid and lymphoid neoplasms in mice. *Leukemia* 2014;28:1343–6.
- Lu C, Lu C, Venneti S, Venneti S, Akalin A, Akalin A, et al. Induction of sarcomas by mutant IDH2. *Genes Develop* 2013;27:1986–98.
- Koivunen P, Koivunen P, Lee S, Lee S, Duncan CG, Duncan CG, et al. Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation. *Nature* 2012;483:484–8.
- Akbay EA, Moslehi J, Christensen CL, Saha S, Tchaicha JH, Ramkissoon SH, et al. D-2-hydroxyglutarate produced by mutant IDH2 causes cardiomyopathy and neurodegeneration in mice. *Genes Devel* 2014;28:479–90.
- Kats LM, Reschke M, Taulli R, Pozdnyakova O, Burgess K, Bhargava P, et al. Proto-oncogenic role of mutant IDH2 in leukemia initiation and maintenance. *Cell Stem Cell* 2014;14:329–41.
- Sasaki M, Knobbe CB, Munger JC, Lind EF, Brenner D, Brüstle A, et al. IDH1 (R132H) mutation increases murine haematopoietic progenitors and alters epigenetics. *Nature* 2012;488:656–9.
- Sasaki M, Sasaki M, Knobbe CB, Knobbe CB, Itsumi M, Itsumi M, et al. D-2-hydroxyglutarate produced by mutant IDH1 perturbs collagen maturation and basement membrane function. *Genes Devel* 2012;26:2038–49.
- Hirata M, Sasaki M, Cairns RA, Inoue S, Puvindran V, Li WY, et al. Mutant IDH is sufficient to initiate enchondromatosis in mice. *Proc Natl Acad Sci* 2015;112:2829–34.
- Saha SK, Parachoniak CA, Ghanta KS, Fitamant J, Ross KN, Najem MS, et al. Mutant IDH inhibits HNF-4 $\alpha$  to block hepatocyte differentiation and promote biliary cancer. *Nature* 2014;513:110–4.
- Chaturvedi A, Araujo Cruz MM, Jyotsana N, Sharma A, Yun H, Görlich K, et al. Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML. *Blood* 2013;122:2877–87.
- Chen C, Chen C, Liu Y, Liu Y, Lu C, Lu C, et al. Cancer-associated IDH2 mutants drive an acute myeloid leukemia that is susceptible to Brd4 inhibition. *Genes Develop* 2013;27:1974–85.
- Ogawara Y, Katsumoto T, Aikawa Y, Shima Y, Kagiyama Y, Soga T, et al. IDH2 and NPM1 mutations cooperate to activate Hoxa9/Meis1 and

- hypoxia pathways in acute myeloid leukemia. *Cancer Res* 2015;75:2005–16.
32. Cancer Genome Atlas Research N, Brat DJ, Verhaak RG, Aldape KD, Yung WK, Salama SR, et al. Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. *N Engl J Med* 2015;372:2481–98.
  33. Eckel-Passow JE, Lachance DH, Molinaro AM, Walsh KM, Decker PA, Sicotte H, et al. Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors. *N Engl J Med* 2015;372:2499–508.
  34. Paschka P, Schlenk RF, Gaidzik VI, Habdank M, Kronke J, Bullinger L, et al. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. *J Clin Oncol* 2010;28:3636–43.
  35. DiNardo CD, Ravandi F, Agresta S, Konopleva M, Takahashi K, Kadia T, et al. Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML. *Am J Hematol* 2015;90:732–6.
  36. Wang F, Travins J, DeLaBarre B, Penard-Lacronique V, Schalm S, Hansen E, et al. Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation. *Science* 2013;340:622–6.
  37. Losman JA, Looper RE, Koivunen P, Lee S, Schneider RK, McMahon C, et al. (R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible. *Science* 2013;339:1621–5.
  38. DiNardo C, Stein EM, Altman JK, Collins R, DeAngelo DJ, Fathi AT, et al. AG-221, an oral, selective, first-in-class, potent inhibitor of the IDH2 mutant enzyme, induced durable responses in a phase 1 study of IDH2 mutation-positive advanced hematologic malignancies [abstract]. In: Proceedings of the 20th Congress of the European Hematology Association; 2015 Jun 11–14; Vienna, Austria. The Hague (the Netherlands): EHA; 2015. Abstract nr P569.
  39. Burris H, Mellingerhoff JK, Maher E, Wen PY, Beeram M, Touat M, et al. The first reported results of AG-120, a first-in-class, potent inhibitor of the IDH1 mutant protein, in a phase 1 study of patients with advanced IDH1-mutant solid tumors, including gliomas [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2015 Nov 5–9; Boston, MA. Philadelphia (PA): AACR; 2015. Abstract nr PL04-05.
  40. Jin G, Pirozzi CJ, Chen LH, Lopez GY, Duncan CG, Feng J, et al. Mutant IDH1 is required for IDH1 mutated tumor cell growth. *Oncotarget* 2012;3:774–82.
  41. Ma S, Jiang B, Deng W, Gu ZK, Wu FZ, Li T, et al. D-2-hydroxyglutarate is essential for maintaining oncogenic property of mutant IDH-containing cancer cells but dispensable for cell growth. *Oncotarget* 2015;6:8606–20.
  42. Rohle D, Popovici-Muller J, Palaskas N, Turcan S, Grommes C, Campos C, et al. An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. *Science* 2013;340:626–30.
  43. Lu C, Ward PS, Kapoor GS, Rohle D, Turcan S, Abdel-Wahab O, et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. *Nature* 2012;483:474–8.
  44. Achouri Y, Noel G, Vertommen D, Rider MH, Veiga-Da-Cunha M, Van Schaftingen E. Identification of a dehydrogenase acting on D-2-hydroxyglutarate. *Biochem J* 2004;381:35–42.
  45. Reitman ZJ, Sinenko SA, Spana EP, Yan H. Genetic dissection of leukemia-associated IDH1 and IDH2 mutants and D-2-hydroxyglutarate in *Drosophila*. *Blood* 2015;125:336–45.
  46. Chowdhury R, Yeoh KK, Tian YM, Hillringhaus L, Bagg EA, Rose NR, et al. The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases. *EMBO Rep* 2011;12:463–9.
  47. Xu W, Yang H, Liu Y, Yang Y, Wang P, Kim SH, et al. Oncometabolite 2-Hydroxyglutarate Is a Competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases. *Cancer Cell* 2011;19:17–30.
  48. Loenarz C, Schofield CJ. Physiological and biochemical aspects of hydroxylations and demethylations catalyzed by human 2-oxoglutarate oxygenases. *Trends Biochem Sci* 2011;36:7–18.
  49. Delhommeau F, Dupont S, Della Valle V, James C, Trannoy S, Masse A, et al. Mutation in TET2 in myeloid cancers. *N Engl J Med* 2009;360:2289–301.
  50. Moran-Crusio K, Reavie L, Shih A, Abdel-Wahab O, Ndiaye-Lobry D, Lobry C, et al. Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. *Cancer Cell* 2011;20:11–24.
  51. Kroeze LI, Aslanyan MG, van Rooij A, Koorenhof-Scheele TN, Massop M, Carell T, et al. Characterization of acute myeloid leukemia based on levels of global hydroxymethylation. *Blood* 2014;124:1110–8.
  52. Noushmehr H, Weisenberger DJ, Diefes K, Phillips HS, Pujara K, Berman BP, et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. *Cancer Cell* 2010;17:510–22.
  53. Turcan S, Fabius AW, Borodovsky A, Pedraza A, Brennan C, Huse J, et al. Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT inhibitor decitabine. *Oncotarget* 2013;4:1729–36.
  54. Borodovsky A, Salmasi V, Turcan S, Fabius AW, Baia GS, Eberhart CG, et al. 5-azacytidine reduces methylation, promotes differentiation and induces tumor regression in a patient-derived IDH1 mutant glioma xenograft. *Oncotarget* 2013;4:1737–47.
  55. Flavahan WA, Drier Y, Liau BB, Gillespie SM, Venteicher AS, Stemmer-Rachamimov AO, et al. Insulator dysfunction and oncogene activation in IDH mutant gliomas. *Nature* 2016;529:110–4.
  56. Cairns RA, Mak TW. Oncogenic isocitrate dehydrogenase mutations: mechanisms, models, and clinical opportunities. *Cancer Discov* 2013;3:730–41.
  57. Parker SJ, Metallo CM. Metabolic consequences of oncogenic IDH mutations. *Pharmacol Thera* 2015;152:54–62.
  58. Reitman ZJ, Jin G, Karoly ED, Spasojevic I, Yang J, Kinzler KW, et al. Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome. *Proc Natl Acad Sci USA* 2011;108:3270–5.
  59. Oizel K, Gratas C, Nadaradjane A, Oliver L, Vallette FM, Pecqueur C. D-2-Hydroxyglutarate does not mimic all the IDH mutation effects, in particular the reduced etoposide-triggered apoptosis mediated by an alteration in mitochondrial NADH. *Cell Death Dis* 2015;6:e1704.
  60. Shi J, Sun B, Shi W, Zuo H, Cui D, Ni L, et al. Decreasing GSH and increasing ROS in chemosensitivity gliomas with IDH1 mutation. *Tumour Biol* 2015;36:655–62.
  61. Carey BW, Finley LW, Cross JR, Allis CD, Thompson CB. Intracellular alpha-ketoglutarate maintains the pluripotency of embryonic stem cells. *Nature* 2015;518:413–6.
  62. Izquierdo-Garcia JL, Viswanath P, Eriksson P, Cai L, Radoul M, Chaumeil MM, et al. IDH1 mutation induces reprogramming of pyruvate metabolism. *Cancer Res* 2015;75:2999–3009.
  63. Chan SM, Thomas D, Corces-Zimmerman MR, Xavy S, Rastogi S, Hong WJ, et al. Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia. *Nat Med* 2015;21:178–84.
  64. Leonardi R, Subramanian C, Jackowski S, Rock CO. Cancer-associated isocitrate dehydrogenase mutations inactivate NADPH-dependent reductive carboxylation. *J Biol Chem* 2012;287:14615–20.
  65. Tateishi K, Wakimoto H, Iafate AJ, Tanaka S, Loebel F, Lelic N, et al. Extreme vulnerability of IDH1 mutant cancers to NAD<sup>+</sup> depletion. *Cancer Cell* 2015;28:773–84.
  66. Koivunen P, Lee S, Duncan CG, Lopez G, Lu G, Ramkissoon S, et al. Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation. *Nature* 2012;483:484–8.
  67. Chesnelong C, Chaumeil MM, Blough MD, Al-Najjar M, Stechishin OD, Chan JA, et al. Lactate dehydrogenase A silencing in IDH mutant gliomas. *Neuro-Oncology* 2014;16:686–95.
  68. Sasaki M, Knobbe CB, Itsumi M, Elia AJ, Harris IS, Chio II, et al. D-2-hydroxyglutarate produced by mutant IDH1 perturbs collagen maturation and basement membrane function. *Gen Devel* 2012;26:2038–49.
  69. Fathi AT, Sadrzadeh H, Borger DR, Ballen KK, Amrein PC, Attar EC, et al. Prospective serial evaluation of 2-hydroxyglutarate, during treatment of newly diagnosed acute myeloid leukemia, to assess disease activity and therapeutic response. *Blood* 2012;120:4649–52.
  70. Choi C, Ganji SK, DeBerardinis RJ, Hatanpaa KJ, Rakheja D, Kovacs Z, et al. 2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas. *Nat Med* 2012;18:624–9.
  71. Andronesi OC, Loebel F, Bogner W, Marjanska M, Vander Heiden MG, Iafate AJ, et al. Treatment response assessment in IDH-mutant glioma patients by non-invasive 3D functional spectroscopic mapping of 2-hydroxyglutarate. *Clin Cancer Res* . 2015 Nov 3. [Epub ahead of print].
  72. de la Fuente MI, Young RJ, Rubel J, Rosenblum M, Tisnado J, Briggs S, et al. Integration of 2-hydroxyglutarate-proton magnetic resonance spectroscopy into clinical practice for disease monitoring in isocitrate dehydrogenase-mutant glioma. *Neuro-Oncol* . 2015. [Epub ahead of print].
  73. Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. *N Engl J Med* 2013;368:2059–74.